EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Stipulations of cell and gene therapy and the ties to biomanufacturing

Justin Allisha, Juthika Das, Thomas Dunnigan, Susan T Sharfstein iD, Payel Datta iD

Biotechnology Progress · 2025

DOI: 10.1002/btpr.3521 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biotechnology Progress, 2025. Verfasst von Justin Allisha und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Life Sciences, Albany College of Pharmacy and Health Sciences, Albany, New York, USA. Hauptthemen laut MEDLINE: Genetic Therapy, Cell- and Tissue-Based Therapy, Biotechnology. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 129 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cell and gene therapy (CGT) products are emerging and innovative biopharmaceuticals that hold promise for treating diseases that are otherwise beyond the scope of conventional medicines. The evolution of CGT from a research idea to a promising therapeutic product is due to the complementary advancements across various scientific disciplines. First, the innovations and advancements in gene editing and delivery technology have provided fundamental tools to manipulate genes and cells for therapeutic pursuits. Second, advancements in applied and translational research, including how clinical trials are designed, performed, evaluated, and analyzed, have transformed the technology into a potential therapeutic product. Third, advancements in scaling up the production of CGT products have been critical in delivering the product for preclinical studies, clinical trials, and approved treatments. In parallel, regulatory requirements have continuously evolved, with lessons learned from translational studies and biomanufacturing. These combined efforts have transformed CGT products from a promising concept into a reality with the potential to treat a wide range of diseases. However, continued R&D and regulatory oversight are crucial to further improve the safety, efficacy, and accessibility of CGT products.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyCell- and Tissue-Based TherapyBiotechnologyHumansGene EditingAnimalsTranslational Research, Biomedical

Stichwörter der Autor:innen

CAR Tbiomanufacturingcell therapygene editinggene therapynon‐viral delivery systemsviral‐based vectors

Autor:innen und Institutionen

  • Department of Life Sciences, Albany College of Pharmacy and Health Sciences, Albany, New York, USA.
  • Department of Nanoscale Science and Engineering and The RNA Institute, University at Albany, State University of New York, Albany, New York, USA.

ORCID-Profile: Susan T Sharfstein, Payel Datta

Zitieren

APA

Allisha, J., Das, J., Dunnigan, T., Sharfstein, S. T., & Datta, P. (2025). Stipulations of cell and gene therapy and the ties to biomanufacturing. Biotechnology Progress. https://doi.org/10.1002/btpr.3521

Vancouver

Allisha J, Das J, Dunnigan T, Sharfstein ST, Datta P. Stipulations of cell and gene therapy and the ties to biomanufacturing. Biotechnology Progress. 2025. doi:10.1002/btpr.3521

BibTeX
@article{Allisha2025,
  author = {Allisha, Justin and Das, Juthika and Dunnigan, Thomas and Sharfstein, Susan T and Datta, Payel},
  title = {Stipulations of cell and gene therapy and the ties to biomanufacturing},
  journal = {Biotechnology Progress},
  year = {2025},
  doi = {10.1002/btpr.3521}
}
Kostenlos starten →